Zhou Ruixiang, Weng Fangzhong, Dai Wei, Yan Jun
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2016 Mar;28(3):241-5.
To investigate the organ protective effects and the timing of continuous blood purification (CBP) in the treatment of severe sepsis.
A double-blind randomized controlled trial was conducted. Seventy-four patients with severe sepsis aged between 35 years and 80 years with acute physiology and chronic health evaluation Ⅱ (APACHEⅡ) scores over 20 admitted to Department of Critical Care Medicine of the First Hospital of Wuhan from January 2013 to January 2015 were enrolled. They were divided into control group (n = 37) and treatment group (n = 37) by random number table method. All patients in these two groups received conventional therapy following the guidelines for management of severe sepsis in 2012. In addition the patients in treatment group received continuous veno-venous hemofiltration (CVVH). The critical score, liver and kidney function indexes, etc., levels of pro-inflammatory cytokines in plasma and ultra filtrate before and 24, 48, and 72 hours after treatment, and the clinical picture 2 weeks after treatment in two groups were observed.
APACHE Ⅱ scores, multiple organ dysfunction syndrome (MODS) scores, Murray scores of acute lung injury, and systemic inflammatory response syndrome (SIRS) scores of the patients of the above two groups were gradually declined after the treatment. The levels of white blood cell count (WBC), procalcitonin (PCT), lactate (Lac), tumor necrosis factor-α (TNF-α), interleukins (IL-6 and IL-8), and endotoxin gradually lowered. Levels of blood urea nitrogen (BUN), serum creatinine (SCr), alanine transaminase (ALT) and the oxygenation index (PaO2/FiO2) showed a tendency of lowering. There were statistically significant differences in scores of critical illness, WBC, PCT, Lac, pro-inflammatory cytokine, liver and kidney function indexes, etc. between treatment group and control group 48 hours after treatment (APACHE Ⅱ score: 15.5±4.7 vs. 20.3±5.3, MODS score: 4.6±1.4 vs. 7.3±2.2, Murray score: 1.4±0.5 vs. 1.7±0.6, SIRS score: 2.9±0.8 vs. 3.7±1.0, WBC (×109/L): 1.1±0.5 vs. 1.6±0.5, PCT (μg/L): 26.7±12.0 vs. 32.4±14.1, Lac (mmol/L): 7.6±2.2 vs. 9.3±2.8, TNF-α (μg/L): 96.3±17.4 vs. 153.4±24.2, IL-6 (μg/L): 146.8±20.6 vs. 213.8±29.2, IL-8 (μg/L): 287.1±43.6 vs. 354.5±56.2, endotoxin (kEU/L): 1.4±0.5 vs. 2.6±0.8, BUN (mmol/L): 8.7±3.6 vs. 18.5±6.4, SCr (μmol/L): 143±39 vs. 197±42, ALT (U/L): 141±27 vs. 183±34, PaO2/FiO2 (mmHg, 1 mmHg = 0.133 kPa): 150.3±45.4 vs. 124.7±32.1, all P < 0.05], and the difference was significant up to 72 hours. In the treatment group, TNF-α, IL-6, IL-8, and endotoxin could be decreased in the filtrate 24 hours and 48 hours after treatment and they correlated with the lowering tendency of their plasma levels. Compared with the control group, CVVH based on conventional treatment of severe sepsis could significantly reduce the incidence of MODS (10.8% vs. 29.7%, χ2 = 4.423, P = 0.038) and mortality (5.4% vs. 13.5%, χ2 = 4.674, P = 0.032), and remarkably shortened the duration of mechanical ventilation (days: 3.1±0.6 vs. 5.3±1.7, t = 2.103, P = 0.045), and the length of intensive care unit (ICU) stay (days: 8.5±1.7 vs. 13.2±2.4, t = 2.245, P = 0.042).
Early CBP can decrease the level of pro-inflammatory cytokines, prevent MODS, and remarkably improve the prognosis of patients with severe sepsis.
探讨连续性血液净化(CBP)在治疗严重脓毒症中的器官保护作用及时机。
进行一项双盲随机对照试验。选取2013年1月至2015年1月在武汉市第一医院重症医学科收治的74例年龄在35岁至80岁之间、急性生理与慢性健康状况评分Ⅱ(APACHEⅡ)超过20分的严重脓毒症患者。采用随机数字表法将其分为对照组(n = 37)和治疗组(n = 37)。两组所有患者均按照2012年严重脓毒症管理指南接受常规治疗。此外,治疗组患者接受连续性静脉-静脉血液滤过(CVVH)。观察两组患者治疗前及治疗后24、48和72小时的病情严重程度评分、肝肾功能指标等、血浆及超滤液中促炎细胞因子水平,以及治疗2周后的临床情况。
上述两组患者治疗后APACHEⅡ评分、多器官功能障碍综合征(MODS)评分、急性肺损伤的Murray评分及全身炎症反应综合征(SIRS)评分均逐渐下降。白细胞计数(WBC)、降钙素原(PCT)、乳酸(Lac)、肿瘤坏死因子-α(TNF-α)、白细胞介素(IL-6和IL-8)及内毒素水平逐渐降低。血尿素氮(BUN)、血清肌酐(SCr)、谷丙转氨酶(ALT)及氧合指数(PaO2/FiO2)呈下降趋势。治疗48小时后,治疗组与对照组在病情严重程度评分、WBC、PCT、Lac、促炎细胞因子、肝肾功能指标等方面差异有统计学意义(APACHEⅡ评分:15.5±4.7 vs. 20.3±5.3,MODS评分:4.6±1.4 vs. 7.3±2.2,Murray评分:1.4±0.5 vs. 1.7±0.6,SIRS评分:2.9±0.8 vs. 3.7±1.0,WBC(×109/L):1.1±0.5 vs. 1.6±0.5,PCT(μg/L):26.7±12.0 vs. 32.4±14.1,Lac(mmol/L):7.6±2.2 vs. 9.3±2.8,TNF-α(μg/L):96.3±17.4 vs. 153.4±24.2,IL-6(μg/L):146.8±20.6 vs. 213.8±29.2,IL-8(μg/L):287.1±- 43.6 vs. 354.5±56.2,内毒素(kEU/L):1.4±0.5 vs. 2.6±0.8,BUN(mmol/L):8.7±3.6 vs. 18.5±6.4,SCr(μmol/L):143±39 vs. 197±42,ALT(U/L):141±27 vs. 183±34,PaO2/FiO2(mmHg,1 mmHg = 0.133 kPa):150.3±45.4 vs. 124.7±32.1,均P < 0.05),且差异持续至72小时。治疗组治疗后24小时和48小时超滤液中TNF-α、IL-6、IL-8及内毒素水平降低,且与血浆水平降低趋势相关。与对照组相比,基于常规治疗的严重脓毒症CVVH治疗可显著降低MODS发生率(10.8% vs. 29.7%,χ2 = 4.423,P = 0.038)和死亡率(5.4% vs. 13.5%,χ2 = 4.674,P = 0.032),并显著缩短机械通气时间(天:3.1±0.6 vs. 5.3±1.7,t = 2.103,P = 0.045)及重症监护病房(ICU)住院时间(天:8.5±1.7 vs. 13.2±2.4,t = 2.245,P = 0.042)。
早期CBP可降低促炎细胞因子水平,预防MODS,显著改善严重脓毒症患者的预后。